Literature DB >> 12396324

Infection with hepatitis C virus among intravenous-drug users: prevalence, genotypes and risk-factor-associated behaviour patterns in Thailand.

T Hansurabhanon1, C Jiraphongsa, P Tunsakun, R Sukbunsung, B Bunyamanee, P Kuirat, S Meedsen, W Waedeng, A Theamboonlers, Y Poovorawan.   

Abstract

Hepatitis C virus (HCV) infection, a major problem worldwide, is usually transmitted parenterally or by use of contaminated needles among intravenous-drug users (IVDU). In a cross-sectional study, demographic data were collected and behaviour patterns investigated in interviews with 453, consenting IVDU. Blood samples were collected from each interviewee and checked for anti-HCV antibodies and, in a PCR-based assay, for the RNA of HCV. Almost all (92.5%) of the IVDU investigated were found positive for anti-HCV and/or the viral RNA. Most (73.5%) of those positive for HCV RNA were found to be infected with genotype 3a alone, the rest being infected with 1b (17.9%), 6a (3.5%), 3b (1.4%), 1a (1.0%), or both 3a and 6a (2.1%) or having non-typable infections (0.6%). Curiously, 26.0% of those who appeared seronegative for anti-HCV were positive for HCV RNA. The longer an interviewee had been using intravenous drugs, the more likely he or she was to be infected with HCV. Among the IVDU, the sharing of needles, syringes and/or other drug-related paraphernalia appeared to be the behaviour carrying the highest risk of HCV infection, giving an adjusted odds ratio and (95% confidence interval) of 4.84 (1.88-12.43). Programmes of needle and syringe exchange should probably be implemented among IVDU in Thailand and elsewhere, to slow the transmission of HCV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396324     DOI: 10.1179/000349802125001465

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  8 in total

1.  Hepatitis C virus infection among people who inject drugs in Bangkok, Thailand, 2005-2010.

Authors:  Michael Martin; Suphak Vanichseni; Wanna Leelawiwat; Rapeepan Anekvorapong; Boonyos Raengsakulrach; Thitima Cherdtrakulkiat; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Janet M McNicholl; Somyot Kittimunkong; Marcel E Curlin; Kachit Choopanya
Journal:  WHO South East Asia J Public Health       Date:  2019-04

2.  Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users.

Authors:  Dale M Netski; Xiao-Hong Wang; Shruti H Mehta; Kenrad Nelson; David Celentano; Satawat Thongsawat; Niwat Maneekarn; Vinai Suriyanon; Jaroon Jittiwutikorn; David L Thomas; John R Ticehurst
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

3.  Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand.

Authors:  Nicole Ngo-Giang-Huong; Gonzague Jourdain; Wasna Sirirungsi; Luc Decker; Woottichai Khamduang; Sophie Le Coeur; Surat Sirinontakan; Rosalin Somsamai; Karin Pagdi; Jittapol Hemvuttiphan; Kenneth McIntosh; Francis Barin; Marc Lallemant
Journal:  Int J Infect Dis       Date:  2010-01-03       Impact factor: 3.623

4.  Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Nikolaus Jilg; Lei Zhao; Dahlene N Fusco; Hong Zhao; Kaku Goto; Du Cheng; Esperance A Schaefer; Leiliang Zhang; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Lee F Peng; Niwat Maneekarn; Raymond T Chung; Wenyu Lin
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

5.  Single Clinical Practice's Report of Testing Initiation, Antibody Clearance, and Transmission of Hepatitis C Virus (HCV) in Infants of Chronically HCV-Infected Mothers.

Authors:  Aswine Bal; Anna Petrova
Journal:  Open Forum Infect Dis       Date:  2016-02-08       Impact factor: 3.835

6.  Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era.

Authors:  Kittiyod Poovorawan; Wirichada Pan-Ngum; Lisa J White; Ngamphol Soonthornworasiri; Polrat Wilairatana; Rujipat Wasitthankasem; Pisit Tangkijvanich; Yong Poovorawan
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

7.  Combating the wrath of viral hepatitis in India.

Authors:  Sandeep Satsangi; Radha K Dhiman
Journal:  Indian J Med Res       Date:  2016-07       Impact factor: 2.375

8.  Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan.

Authors:  Ming-Ying Lu; Chun-Ting Chen; Yu-Lueng Shih; Pei-Chien Tsai; Meng-Hsuan Hsieh; Chung-Feng Huang; Ming-Lun Yeh; Ching-I Huang; Shu-Chi Wang; Yi-Shan Tsai; Yu-Min Ko; Ching-Chih Lin; Kuan-Yu Chen; Yu-Ju Wei; Po-Yao Hsu; Cheng-Ting Hsu; Tyng-Yuan Jang; Ta-Wei Liu; Po-Cheng Liang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu; Wen-Yu Chang
Journal:  Sci Rep       Date:  2021-04-20       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.